Gerry Brunk

Lumira Ventures is a North America healthcare venture capital firm that provides capital and operating expertise to life science companies developing innovative products that solve significant unmet needs of patients and healthcare providers. The firm has partners in Toronto, Montreal, Vancouver and Boston.

Sound Blade is developing handheld ultrasound-guided histotripsy technology for a range of clinical indications.

Endogenex, a clinical stage company founded in partnership with Mayo Clinic, is focused on shifting the treatment paradigm for people living with Type 2 Diabetes. Current diabetes care focuses on the downstream consequences of this metabolic disease by targeting insulin resistance with medications and insulin replacement therapy. Endogenex’s goal is to reset the cellular signaling of the duodenum to help the body better manage blood sugar levels, via its endoscopic ReCET Procedure and the novel application of non-thermal pulsed electric field therapy to eliminate poorly signaling cells and induce regrowth of healthy cells that may restore proper metabolic signaling and potentially slow disease progression.

HistoSonics is a privately held medical device company developing non-invasive platforms and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, brain, and others. HistoSonics has offices in Ann Arbor, Michigan, and Minneapolis, Minnesota. The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy.

Cadence is developing a novel neuromodulation therapy for treating pediatric and adult patients with focal drug resistant epilepsy, originally developed at Mayo Clinic. The therapy utilizes chronic subthreshold cortical stimulation to modulate EEG biomarkers associated with epilepsy to reduce or eliminate seizures.

enGene Inc. is a clinical-stage biotechnology company developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical models, enGene's DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract and urinary tract.

GenEp, Inc. is a privately held pre-clinical stage biotechnology company, spun out of the University of Virginia, creating therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment resistant epilepsies.

Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company developing a novel therapy to restore smell and flavor function. The chronic loss of smell and flavor is a condition affecting at least 5% of the U.S. population with a similar incidence in Europe and Asia. The condition is now recognized as a widely prevalent long-term condition suffered by many patients who have recovered from COVID-19.

Corvia Medical (formerly DC Devices) is developing the first trans-catheter device for diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF)